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Abstract (250 words)  
Purpose 
We conducted a systematic review and individual patient data (IPD) meta-analysis to 
examine the utility of cystatin C for evaluation of glomerular function in children with 
cancer.  
Methods 
Eligible studies evaluated the accuracy of cystatin C for detecting poor renal function in 
children undergoing chemotherapy. Study quality was assessed using QUADAS-2. Authors of 
four studies shared IPD. We calculated the correlation between log cystatin C and GFR 
stratified by study and measure of cystatin C. We dichotomized the reference standard at 
GFR 80 ml/min/1.73m2 and stratified cystatin C at 1mg/l, to calculate sensitivity and 
specificity in each study and according to age group (0-4, 5-12 and ≥13 years). We used 
logistic regression to estimate the association of impaired renal function with log cystatin C 
and quantified diagnostic accuracy using the Area Under the ROC Curve (AUC). 
Results 
Six studies, which used different test and reference standard thresholds, suggested that 
cystatin C has the potential to monitor renal function in children undergoing chemotherapy 
for malignancy. IPD data (504 samples, 209 children) showed that cystatin C has poor 
sensitivity (63%) and moderate specificity (89%). The AUC for the combined data set was 
0.890 (95% CI 0.826, 0.951). Diagnostic accuracy appeared to decrease with age. 
Conclusions 
Cystatin C has better diagnostic accuracy than creatinine as a test for glomerular 
dysfunction in young people undergoing treatment for cancer. Diagnostic accuracy is not 
sufficient for it to replace current reference standards for predicting clinically relevant 
impairments that may alter dosing of important nephrotoxic agents. 
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Introduction 
Causes of glomerular dysfunction in children with cancer include direct and indirect effects 
of the malignant process and its treatment, and a range of potentially additive side effects 
from chemotherapy, radiotherapy, surgery, immunotherapy or supportive treatment. 
Glomerular impairment is variable in severity and potential reversibility. Renal dysfunction 
frequently impacts on the management of children with cancer, and in particular may have 
important implications for the ability to deliver optimal chemotherapy.1,2 
 
It is important to evaluate glomerular function in children with cancer since glomerular 
filtration is a major determinant of renal excretion and hence the systemic clearance of 
some important chemotherapy (e.g. carboplatin) and supportive care drugs (e.g. aciclovir).2 
Accurate assessment is important since the therapeutic index of many of these drugs is 
narrow, with even relatively small differences in systemic exposure leading to potential 
under-treatment and hence poorer anti-tumour efficacy or over-dosage and risk of 
significant toxicity. However, current approaches to measuring glomerular function in 
children have important limitations, including their accuracy and practicability.3 A simple, 
reliable, blood test capable of evaluating glomerular function accurately would be valuable. 
 
Plasma cystatin C is a promising new serum marker for monitoring renal function. Several 
studies have investigated its utility as a measure of glomerular function, and some have 
suggested that it should be used in clinical practice. However, we are not aware of any 
previous systematic review of these studies. 
 
Individual patient data (IPD) pooled analysis of data from randomized trials can facilitate 
consistent approaches to the control of patient characteristics at baseline and has particular 
advantages for subgroup analyses. 4,5 It has recently been promoted for the synthesis of 
diagnostic accuracy data, but few reviews of diagnostic test accuracy data have used IPD.6 
Potential benefits of diagnostic IPD analysis include the use of information about the 
receiver operating characteristic (ROC) curve that is not captured in summary (2×2) tables of 
diagnostic accuracy, the potential to examine diagnostic accuracy within patient subgroups, 
and enhanced statistical precision compared with analyses of individual studies. We 
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examined the utility of cystatin C for evaluation of glomerular function in children with 
cancer based on IPD combined from four studies, and compared results to those obtained 
using summary data. 
 
Methods 
Literature searches 
Diagnostic test accuracy (DTA) studies were identified by searching MEDLINE, EMBASE, 
Biosis, Science Citation Index, and LILACS from inception to June 2009. The MEDLINE search 
was updated in March 2015. In addition, information on studies in progress, unpublished 
research or research reported in the grey literature was sought by searching a range of 
relevant databases including Zetoc, SIGLE, Dissertation Abstracts, the metaRegister of 
Controlled Trials, NTIS and the GrayLit network. The search strategy was based on 
combining terms for the index test (cystatin C) and target condition (renal function), and 
limiting results to studies in children. Full details of the search strategy are available from 
the authors on request.  
 
Selection of studies 
Studies that were eligible for inclusion evaluated the accuracy of cystatin C for the detection 
of poor renal function/reduced GFR in children undergoing chemotherapy against a 
reference standard consisting of 24-hour urine collection, inulin clearance, or radio-isotope 
scans. Two reviewers independently screened the search results. Full text papers were 
assessed for inclusion by one reviewer and checked by a second. Disagreements were 
resolved through consensus. 
 
Extraction of summary data and quality assessment 
Summary data on participants, index test, reference standard, 2x2 tables of diagnostic 
accuracy, sensitivity, specificity and measures of correlation were extracted from the 
published study reports using data extraction forms developed using Microsoft Access. 
Where available, data stratified according to age were extracted separately for different age 
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groups. Study quality was assessed using the QUADAS-2 tool.7 This includes domains 
covering bias due to selection of participants, index test, reference standard and flow and 
timing. The first three domains are also assessed in terms of applicability to the review 
question. Data extraction and quality assessment were carried out by one reviewer and 
checked by a second.  
 
Individual Patient Data 
Authors of the published studies were contacted and invited to take part in the “Cystatin C 
in Childhood Cancer Collaboration” (CCiCCC). They were asked to share the individual 
patient data (IPD) from their study to facilitate analyses that could not be conducted based 
on summary data alone. Facilities were set up to allow secure transfer of data. Authors were 
asked to upload a dataset containing the following data, if available: underlying tumour 
type, chemotherapy type and date of last cycle, other treatment, comorbidity, age, gender, 
height, weight, BMI, number of samples tested for cystatin C, numerical results for each 
cystatin C test, dates of each cystatin C test, number of samples tested using the reference 
standard, numerical results for each reference standard assessment, dates of each 
reference standard assessment, other tests conducted, results of all other tests, if the 
patient did not receive both the cystatin C test and reference standard, reasons for this. The 
data request form is available as a web appendix. 
 
Analysis of summary data 
There were insufficient data to allow diagnostic meta-analysis of summary data, so instead a 
narrative synthesis was presented. Measures of correlation between cystatin C and GFR 
were summarized. Ranges of sensitivity and specificity were calculated. Estimates of 
sensitivity and specificity were plotted in ROC space. 
 
Analysis of individual patient data 
We standardized definitions and categorizations of variables across studies as far as 
practicable, and agreed a common set of variables to be combined from each study. Data 
were combined into a single dataset with an additional variable for study number (1 to 4). 
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When considering cystatin C and creatinine as continuous variables, we log transformed the 
measures because their distributions were right-skewed. We investigated the association 
between cystatin C and GFR (the reference standard): we calculated the correlation 
between log cystatin C and GFR, stratified by study and by cystatin C sample number if 
multiple measures were made in the same individual. For further analyses we selected the 
first sample per person. We dichotomized the GFR reference standard at 80 ml/min/1.73m2, 
with values below this indicating impaired renal function. We dichotomized cystatin C at 
1mg/l, with values above this indicating poor renal function. We used 2x2 tables of 
dichotomized GFR and cystatin C to calculate sensitivity and specificity at these thresholds in 
each study. We used fixed-effect logistic regression to estimate the association of impaired 
renal function (GFR) with the serum markers of renal function (cystatin C and creatinine). 
For these regression models, log cystatin C and log creatinine were converted into z-scores 
with mean zero and standard deviation (SD) one in the combined dataset, enabling 
comparisons of their effects for an equivalent one SD change in each serum marker. We 
fitted separate models for each study and a combined model across the studies that 
included an indicator variable for study number. We quantified diagnostic accuracy using 
the Area Under the ROC Curve (AUC) in models that included (i) log cystatin C, (ii) log 
creatinine and (iii) both log cystatin C and log creatinine, for the studies for which data on 
both of these variables were available. To investigate variation in diagnostic accuracy with 
age we fitted separate models for different age groups (0-4, 5-12 and ≥13 years). As 
sensitivity analyses, we: (1) investigated different cystatin C cut points to establish what 
threshold would provide sensitivity greater than 0.98 and (2) allowed for repeated 
measures of samples within patients, using the ‘somersd’ command after multilevel mixed-
effects logistic regression model in Stata version 14 to calculate the AUC.  
 
Results 
The searches identified 2621 studies, of which six diagnostic cohort studies met inclusion 
criteria.8-13 Two of these were available only in abstract form.9,12 The six studies included 
342 children (range 28 to 99) and more than 545 samples (range 31 to 276; not reported in 
one study). Mean age ranged from 3.2 to 11.3 years and the proportion of girls ranged from 
26% to 64%. The studies included patients with various different cancers. Only one study 
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reported on chemotherapy regimen, which varied between children. Five studies used 
immunonephelometric methods to measure cystatin C concentration; the remaining study 
did not report on how cystatin C was measured. 9 Three studies did not use a threshold to 
dichotomize cystatin C test result8-10: the threshold varied between the remaining three 
studies. Four studies used radioisotope plasma clearance techniques as the reference 
standard to measure GFR as an indicator of kidney function.8-10,12 Two studies used a 
threshold of <90ml/min/1.73m2 and one a threshold of <100ml/min/1.73m2 as an indicator 
of impaired kidney function; the other did not dichotomize GFR. One study used 24-hour 
urine collection creatinine clearance ratio as an estimate of GFR, with the threshold for 
normal GFR varying based on age and gender.13 The final study used inulin clearance 
measured using blood sampling at various time points after injection of polyfructosan, with 
a threshold of <90ml/min/1.73m2 indicating abnormal GFR. A summary of the six published 
studies is provided in Table 1. 
 
The results of the QUADAS-2 assessment are summarized in Web Figure 1. All studies were 
judged at low or unclear risk of bias and concerns regarding applicability for all domains. 
Two studies were judged at low risk of bias for patient spectrum;11,13 four were judged at 
unclear risk of bias as they did not provide sufficient information on how patients were 
enrolled into the studies. Three studies were judged at unclear risk of bias for the flow and 
timing domain as it was unclear whether all enrolled patients contributed to the analysis. 
The only concern regarding applicability was one study12 that used a higher reference 
standard threshold than commonly used to define an abnormal glomerular filtration rate 
(<100 mL/min/1.73m2). 
 
Summary Data 
Three studies provided measures of correlation between cystatin C and the reference 
standard (Web Table 1).9,10,13 Two studies suggested a strong negative correlation and one 
suggested a weaker correlation. Three studies, including one that provided correlation data, 
13 reported data on sensitivity and specificity.11-13 One of these did not provide sufficient 
data to construct a 2x2 table of test performance as it was unclear how many patients were 
classed as having normal/abnormal GFR.12 One study did not provide summary data on 
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either correlation or accuracy. 8 Estimates of sensitivity and specificity plotted in ROC space 
from the three studies which provided data on the accuracy of cystatin C are shown in 
Figure 1.11-13 One study provided estimates of sensitivity and specificity for two different age 
groups and so contributes two points to the graph.13 Sensitivity ranged from 39 to 100%, 
specificity ranged from 79 to 94%. 
 
IPD data 
Four of the six studies agreed to become members of the 5C collaboration and shared their 
data.8,10,11,13 The number of participants and age of included children showed some 
variation from that reported in the summary data reports of these studies (Table 1). The 
total number of participants was 229 (range 22 to 84 per study) and the number of samples 
was 504 (range 68 to 262 per study). The median age at first measure ranged from 2.8 to 
12.1 years. In the IPD, median cystatin C in the individual studies ranged from 0.74 mg/l to 
0.89 mg/l. The median GFR ranged from 86.3 ml/min/1.73m2 to 130.0 ml/min/1.73m2. The 
correlations between log cystatin C and GFR for the first sample per person ranged from -
0.454 to -0.713 (Web Table 1). Correlations between log cystatin C and GFR on the repeated 
samples, where available, were similar. 
 
Estimates of sensitivity and specificity at a cystatin C threshold of 1 mg/l are shown in Table 
2 and Figure 3, which also shows individual ROC plots for each study. Sensitivity ranged from 
53% to 75% and specificity from 86% to 100%. The estimates combining IPD from all four 
studies were sensitivity 63.2% (95% CI 46.0%, 78.2%) and specificity 88.9% (83.6%, 93.0%). 
 
Estimates of area under the ROC curve (AUC) for cystatin C were 0.915 (95% CI 0.829, 1.00) 
for the Lankisch study,13 0.862 (0.775, 0.950) for the Barnfield study10 and 0.792 (0.427, 
1.00) for the Blufpand study11 (Table 3). It was not possible to construct an ROC curve for 
the Gronroos study8 as there were no events of GFR<80ml/min/1.73m2. There was little 
evidence that the AUC varied between studies (interaction p=0.77). The AUC for the 
combined data set, based on the three studies for which individual ROC curves could be 
constructed, was 0.890 (95% CI 0.826, 0.951) which is not considered sufficiently accurate 
for clinical use. Diagnostic accuracy of cystatin C appeared to be highest in the younger age 
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group (AUC 0.945, 95% CI 0.895, 0.996) and to decrease with age (Figure 2). For the 
Barnfield study diagnostic accuracy was substantially greater for cystatin C (AUC 0.862) than 
for creatinine (0.681) and was not improved in the model containing both variables (0.861) 
compared with cystatin C alone (Table 3). For the Blufpand study, diagnostic accuracy was 
also substantially greater for cystatin C (0.792) than for creatinine (0.696) and was improved 
in the model containing both variables (0.883) compared with cystatin C alone. In the 
Lankisch study diagnostic accuracy for cystatin C was 0.915, but data on creatinine were not 
available. 
 
The odds ratios from all logistic regression models are shown in Web Table 2. The 
unadjusted odds ratios per SD increase in log cystatin C for impaired renal function (GFR) 
were 9.0 (95% CI: 3.1, 26.0; p<0.001) in the Barnfield study, 4.6 (1.1, 19.3; p=0.039) in the 
Blufpand study and 7.5 (3.0, 18.9; p<0.001) in the Lankisch study. The unadjusted odds 
ratios per SD increase in log creatinine were lower: 2.2 (1.3, 3.8; p=0.006) and 0.4 (0.1, 1.7; 
p=0.219) in the Barnfield and Blufpand data, respectively. Odds ratios were not substantially 
changed in models that contained both cystatin C and creatinine. Combined across studies, 
the odds ratios per SD increase in log cystatin C were 7.4 (4.0, 13.8; p<0.001) based on the 
first measure and 9.3 (5.8, 14.9; p<0.001) based on all measures. The odds ratio per SD 
increase in log cystatin C was 15.0 (3.1, 71.9) in younger children and 6.1 (2.2, 16.7) in older 
children (p for interaction = 0.727). 
 
Results from sensitivity analyses showed that estimated sensitivity for a cystatin C threshold 
of >0.7 mg/l was 100%, but the corresponding specificity was only 31.6% and more than 
70% of patients would be classified as having 'elevated' cystatin C at this threshold. The AUC 
from the model for cystatin C using all data and allowing for repeated measures per person 
was 0.902 (95% CI 0.861, 0.942); the odds ratio per SD increase in log cystatin C in this 
model was 9.3 (5.8, 14.9; p<0.001; Web Table 2). 
 
Discussion 
Summary of findings 
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We conducted a systematic review and meta-analysis of published summary data and 
individual patient data from diagnostic test accuracy studies of cystatin C for diagnosis of 
impaired renal function in children with cancer. The six available published reports 
suggested that cystatin C has the potential to monitor renal function in children undergoing 
chemotherapy for malignancy, but they used different test and reference standard 
thresholds, and the summary data were impossible to synthesize quantitatively. The IPD 
analyses provided important additional information and led to clearer conclusions than 
those possible with published summary data. They showed that at a threshold of >1mg/l 
cystatin C has limited sensitivity (63%) and moderate specificity (89%) for diagnosis of 
impaired renal function. Using a threshold which achieved sensitivity 0.98 (>0.7 mg/l), 70% 
of the tested population would have an ‘elevated’ cystatin C and require further testing with 
a reference standard test. Diagnostic accuracy for cystatin C was consistent across studies. 
For the two studies for which data were available, diagnostic accuracy of cystatin C was 
clearly greater than that of creatinine. However diagnostic accuracy may not be sufficient to 
justify the use of cystatin C as a screening test for glomerular dysfunction, because of the 
practical implications of incorrect classification of renal function, or the large proportion of 
children in whom a second, definitive test would be required after cystatin C testing. These 
include under-dosing patients with a reduction in anti-cancer efficacy in whom the test 
incorrectly reports renal impairment, and excessive dosing with high risks of severe 
chemotherapy toxicities in those who are incorrectly reported as having sufficient renal 
function.  
 
Strengths and limitations 
The comprehensive and efficient use of IPD data, collected by a collaborative effort from the 
5C group, has allowed us to clearly describe the limits of uncertainty with cystatin C in 
childhood cancer and conclude that this test is not suitable for routine use. Limitations of 
our review include the small number of studies available on this topic and that we were only 
able to obtain IPD data for four of the six identified studies, all of which had very small 
sample sizes (range 22 to 84 children). It is unclear why the other groups declined to 
participate. The summary data available were insufficient to perform standard meta-
analysis and so we were unable to compare the results from summary data meta-analysis 
with IPD meta-analysis. There were some discrepancies between what had been reported in 
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the publications of the studies and the IPD that were provided to us, for example the 
number of samples. While studies investigating other markers are being developed, 
consideration should be given by clinical researchers to regularly enter into collaboration 
with other academics, guided by partners skilled in meta-analysis, to produce results which 
are more precise and globally applicable than any one study group would achieve. 
 
Comparison with existing literature 
Cystatin C has been promoted as a marker of renal function in a variety of conditions, for 
example post-renal transplant in adults14 or children,15 or in adults with malignancy.16 Other 
uses for the marker include the prediction of mortality in adult populations with and 
without renal impairment,17 with high risk conditions such as type 2 diabetes18 or in critical 
care units.19 The clinical utility of cystatin C differs according to the indication.18,19 The 
accuracy of cystatin C based measurements is consistently better than those based on 
creatinine alone, and may be reasonable to use at a population based level.20 However, 
these measurements have previously been shown not to be useful as a basis for 
chemotherapy dosing decisions.21 
 
These findings place cystatin C in a similar situation to existing tests for renal impairment, 
which all have important challenges in their regular clinical use. Routinely measured 
creatinine has insufficient accuracy as a serum marker for renal function, especially in 
children.22 Serum concentrations of creatinine and particularly urea are insensitive, with 
abnormal values not seen until the glomerular filtration rate (GFR) has fallen by 30-50%.8 
GFR can be estimated from formulae including serum creatinine concentration and patient 
height but their utility in determining GFR in children with cancer has been shown to be 
low.23,24 The creatinine clearance method requires accurately timed urine collections which 
are difficult to achieve reliably in children, overestimates GFR due to tubular secretion of 
creatinine and has been shown to be poorly reproducible.25 The inulin clearance method is 
technically difficult since inulin is not routinely measured in clinical laboratories, and 
requires an intravenous inulin infusion and again, a timed urine collection. Where an 
accurate measurement of glomerular function is required to dose chemotherapy, it remains 
important to use plasma radioisotope clearance (e.g. 51Cr-EDTA clearance), despite the 
logistical limitations and exposure to low dose radiation.25 
13 
 
Implications for future research 
Further research could examine whether particular clinical situations alter the clinical utility 
of cystatin C testing. Our data were insufficient to determine if the diagnostic accuracy of 
cystatin C varied between risk groups, for example those exposed to multiple courses of 
nephrotoxic agents, who had documented episodes of acute kidney injury during their 
therapy, or with high body mass index. Such research would benefit from multi-institutional 
collaboration, as clinically important glomerular dysfunction is uncommon in children with 
cancer. 
 
Conclusions 
Cystatin C is more useful than creatinine as a screening test for glomerular dysfunction in 
children and young people undergoing treatment for cancer. However, diagnostic accuracy 
is not sufficiently for it to replace current reference standards for predicting clinically 
relevant impairments that may alter the dosing of important nephrotoxic agents. This 
conclusion could only be firmly reached after combination of individual patient data from 
multiple studies. A limited reading of selected publications could lead clinicians into using 
this test as an easy and effective alternative to assessments using the reference standard, 
and inadvertently producing incorrect decisions leading to avoidable renal impairment or 
under-dosing of anti-cancer agents. Advancing clinical care requires a clear understanding of 
the value of innovations: describing the limitations of new interventions and technologies is 
as important as extolling their benefits, and preventing the uptake of unhelpful approaches 
is a key to effective care as rapidly rolling out beneficial programmes of care. Collaborative 
effort by multinational groups to share and combine data facilitate the evaluations required 
to make judgments about the role of new tests and interventions in clinical care. 
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Table 1: Summary of included studies that provided summary data 
Summary data from published papers 
Study Country N patients 
(samples) 
Median or mean 
age (range), years 
% Male Cystatin C Threshold 
(mg/l)  
Reference standard 
measure (GRF) 
Reference standard 
threshold (ml/min/1.73m2) 
Aydin (2010)9 Turkey 31 (31) 8.2 (2-16) 32 Not stated Radioisotope plasma 
clearance techniques 
NA 
Barnfield (2013)10  UK 99 (NR) 11.9* (0.5-23.6) 74 No threshold used Radioisotope plasma 
clearance techniques 
NA 
Blufpand (2011)11  Holland 68 (276) 3.2 (1.4-7.8)† 74 <90 ± Inulin clearance  
 
<90  
Djemli (2005)12 Canada 28 (46) 9.4* (2-20) 36 >0.675  Radioisotope plasma 
clearance techniques 
<100 
Gronroos (2008)8 Finland 36 (112) 11.3* (2.8-23.9) 42 No threshold used Radioisotope plasma 
clearance techniques  
<90 
Lankisch (2006)13 Germany 80 (80) 8.7* (0.2-17.9) 56 0-1y: >1.17 
>1y: >0.95  
24-Hour urine 
collection; creatinine 
clearance ratio 
0-1y: <64, 1-13y: <120  
14-18y: male <97, female <88 
Individual patient data (IPD) provided to authors 
Study Country N patients 
(samples) 
Median or mean 
age (range), years 
% Male Median (IQR) cystatin C 
(mg/l) 
Median (IQR) 
reference standard 
ml/min/1.73m2 
Reference standard 
threshold (ml/min/1.73m2) 
Aydin (2010)9 Turkey NA NA NA N/A N/A 
 
N/A 
 
Barnfield (2013)10  UK 84 (262) 12.1 (0.5-21.6) 69 0.89 (0.75, 1.04) 86.3 (72.2, 101.5) 
 
<80 
Blufpand (2011)11  Holland 43 (68) 2.8 (0.1-16.9) 63 0.80 (0.69, 0.92) 114.9 (97.4, 129.0) 
 
<80 
Djemli (2005)12 Canada NA NA NA N/A N/A 
 
N/A 
 
Gronroos (2008)8 Finland 22 (94) 8.5 (2.8-17.7) 41 0.74 (0.65, 0.84) 113.1 (100.3, 133.0) 
 
<80 
Lankisch (2006)13 Germany 80 (80) 8.2 (0.2-18.3) 56 0.80 (0.70, 1.00) 130.0 (95.5, 147.0) <80 
N: Number; NA: Not available; * indicates mean age, all other ages are medians; † Reported in paper as range, but IPD data suggests interquartile range (IQR); ± the cystatin 
C-based GFR estimate was calculated as log eGFRcys (ml/min/1.73 m2) = 1.962 + [1.123 x log (1/cystatin C (mg/dl))] 
19 
 Table 2: Estimates of sensitivity and specificity from summary data compared to estimates from IPD data 
Study Summary Data IPD Data 
Cystatin C threshold Sensitivity (95% 
CI)  
Specificity (95% CI) Cystatin C 
threshold 
Sensitivity (95% CI) Specificity (95% CI) 
Barnfield (2013)10  NA NA NA ≥1mg/L 53% (29%, 76%) 86% (75%, 93%) 
Blufpand (2011)11  90mg/L 57% (29%, 82%) 94% (84%, 99%) ≥1mg/L 67% (9%, 99%) 93% (80%, 98%) 
Djemli(2005)12 0.675mg/L 100% 79 ≥1mg/L NA NA 
Gronroos (2008)8 NA NA NA ≥1mg/L NA 100% (85%, 100%) 
Lankisch(2006)13 1-11month 
>1.17mg/L, >1year 
>0.95  
39% (22%, 58%) 84% (70%, 93%) ≥1mg/L 75% (48%, 93%) 86% (75%, 93%) 
Overall     63.2% (46.0%, 
78.2%) 
88.9% (83.6%, 
93.0%) 
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Table 3 AUC for cystatin C, creatinine, and cystatin C and creatinine in the same model, for predicting GFR for the IPD datasets 
 AUC (95% CI) 
Study Cystatin C Creatinine Cystatin C and 
Creatinine 
Barnfield (2013)10 0.862 (0.775, 0.950) 0.681 (0.521, 0.840) 0.861 (0.772, 0.948) 
Blufpand (2011)11 0.792 (0.427, 1.000) 0.696 (0.270, 1.00) 0.883 (0.692, 1.000) 
Gronroos (2008)8 N/A N/A N/A 
Lankisch (2006)13 0.915 (0.829, 1.000) N/A N/A 
Notes: The GFR reference standard was dichotomized at GFR 80 ml/min/1.73m2. Cystatin C and creatinine were log transformed. The Gronroos study 
was excluded because there were no events of GFR<80 ml/min/1.73m2. Creatinine data were not available for analysis in our IPD dataset for the 
Lankisch study as we believe it may have also been used to calculate GFR. 
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Figure 1: Summary ROC plot showing estimates of sensitivity and specificity from studies 
reporting summary data 
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Figure 2: ROC plots for cystatin C for predicting GFR for the IPD datasets, stratified by 
study with additional plot showing summary estimates of sensitivity and specificity 
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Figure 3: ROC plots for cystatin C for predicting GFR for the combined IPD dataset 
stratified according to age group 
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Web Table 1: Estimates of correlation between cystatin C and GFR  
Study Summary Data IPD data, natural log transformed cystatin C 
N (samples) Correlation N Correlation(95% CI) 
Aydin (2010)9  31 (31) -0.42 NA  
Barnfield (2013)10  99 (NR) 0.66 for reciprocal of cystatin C 83 -0.713 (-0.805, -0.588) 
Blufpand (2011)11  68 (276) Not reported 43 -0.568 (-0.742, -0.323) 
Djemli(2005)12 28 (46) Not reported NA  
Gronroos (2008)8 36 (112) Not reported 22 -0.454 (-0.735, -0.040) 
Lankisch(2006)13 80 (80), whole sample -0.70 80 -0.689 (-0.789, -0.553) 
14 (14), age 0-3 years -0.74    
NA: Not available 
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Web Table 2: Odds ratios from logistic regression models of the association of impaired renal function (GFR) with serum markers of renal function 
Data  Variables in the model N (N events) Variable† OR (95% CI) p AUC (95% CI) 
Barnfield (1st measure per person) Cystatin C 83 (19) Cystatin C 9.0 (3.1, 26.0) <0.001 0.862 (0.775, 0.950) 
Creatinine 83 (19) Creatinine 2.2 (1.3, 3.8) 0.006 0.681 (0.521, 0.840) 
Cystatin C and creatinine 83 (19) Cystatin C 8.0 (2.7, 24.4) <0.001 0.860 (0.772, 0.948) 
  Creatinine 1.5 (0.8, 2.8) 0.214  
Blufpand (1st measure per person) Cystatin C 43 (3) Cystatin C 4.6 (1.1, 19.3) 0.039 0.792 (0.427, 1.000) 
Creatinine 43 (3) Creatinine 0.4 (0.1, 1.7) 0.219 0.696 (0.270, 1.000) 
Cystatin C and creatinine 43 (3) Cystatin C 4.7 (1.1, 20.5) 0.041 0.883 (0.692, 1.000) 
  Creatinine 0.4 (0.1, 1.9) 0.226  
Lankisch (1st measure per person) Cystatin C 80 (16) Cystatin C 7.5 (3.0, 18.9) <0.001 0.915 (0.829, 1.000) 
Barnfield, Blufpand and Lankisch (1st 
measure per person, also including an 
indicator variable for study) 
Cystatin C 206 (38) Cystatin C 7.4 (4.0, 13.8) <0.001 0.890 (0.828, 0.951) 
Barnfield, Blufpand and Lankisch 
(allowing for the multiple measures per 
person with study as a random effect) 
Cystatin C 407 (126) Cystatin C 9.3 (5.8, 14.9) <0.001 0.906 (0.872, 0.940) 
Barnfield, Blufpand and Lankisch, age 0-
4y (1st measure per person, also 
including an indicator variable for study) 
Cystatin C 72 (10) Cystatin C 15.0 (3.1, 71.9) 0.001 0.945 (0.895, 0.996) 
Barnfield, Blufpand and Lankisch, age 5-
12y (1st measure per person, also 
including an indicator variable for study) 
Cystatin C 76 (11) Cystatin C 6.1 (2.2, 16.7) <0.001 0.855 (0.729, 0.981) 
Barnfield and Lankisch, age ≥13y (1st 
measure per person, also including an 
indicator variable for study) 
Cystatin C 58 (17) Cystatin C 9.1 (2.6, 32.1) 0.001 0.855 (0.747, 0.964) 
Notes: The GFR reference standard was dichotomised at GFR 80 ml/min/1.73m2. † Cystatin C and Creatinine were log transformed due to skewed distributions and 
converted into z-scores. The z-scores have a mean of zero and standard deviation (SD) of one, enabling the comparison for an equivalent one SD change in each 
serum marker of renal function measurement. The Gronroos study was excluded from models because there were no events of GFR<80 ml/min/1.73m2 for the first 
measure per person. Creatinine data were not available for analysis in our IPD dataset for the Lankisch study as we believe it may have also been used to calculate 
GFR. The Blufpand study was dropped from the combined model age ≥13y because there were no events in this study for this age group, this resulted in three 
people being dropped from this model.  
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Web Figure 1: Proportion of studies rated as high, low or unclear for each QUADAS-2 bias and applicability domains 
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Web Appendix: Data collection form 
 
It would be very helpful if you could provide data based on the following structure. 
However, we will accept data in any format which we will re-structure as necessary. 
 
1. Underlying tumour type  
Diagnosis under treatment, coded as 
1 =  Acute lymphoblastic leukaemia 
2 =  Acute myeloid leukaemia 
3 =  Other leukaemia 
4 =  Hodgkins lymphoma 
5 =  Non-Hodgkins lymphoma 
6 =  Low-grade brain tumour (I-II) 
7 =  High-grade brain tumour (III-IV) 
8 =  ‘High risk’ neuroblastoma 
9 =  Other neuroblastoma 
10 =  Retinoblastoma 
11 =  Wilm’s tumour 
12 =  Other renal tumour 
13 =  Hepatoblastoma 
14 =  Other liver tumor 
15 =  Osteosarcoma 
16 =  Ewing’s sarcoma 
17 =  Rhabdomyosarcoma 
18 =  Other sarcoma 
19 =  Germ cell/gonadal neoplasm 
20 =  Carcinoma/melanoma 
21 =  LCH 
22 =  Other 
999 =  Unknown 
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2. Chemotherapy type and date of last cycle 
Specify the most recent chemotherapy cycle (in words/by acronym) (Will require a 
description of each chemotherapy protocol included from each study). Specify ‘Unknown’ if 
unknown. 
 
3. Other treatment 
Specify any other treatment being given at time of testing. Specify ‘Unknown’ if unknown. 
 
4. Comorbidity 
Specify any other comorbidity at time of testing. Specify ‘Unknown’ if unknown. 
 
5. Age 
Age in months at time of testing; 999 if missing 
 
6. Gender 
Male   1 
Female  2 
Data missing  999 
 
7. Height 
Height in cm; Data missing  999 
 
8. Weight 
Weight in kg; Data missing  999 
 
9. BMI 
Numerical; Data missing  999 
 
10. Number of samples tested for Cystatin C 
Numerical; Data missing  999 
 
11. Numerical results for each Cystatin C test 
29 
Numerical; Data missing  999 
 
12. Dates of each Cystatin C test 
  DD/MM/YYYY; Data missing  999 
 
13. Number of samples tested using the reference standard 
Numerical; Data missing  999 
 
14. Numerical results for each reference standard assessment 
Numerical; Data missing  999 
 
15. Dates of each reference standard assessment 
DD/MM/YYYY; Data missing  999 
 
16. Other tests conducted 
Text; Specify ‘Unknown’ if unknown. 
 
17. Details of all other test results 
Text; Specify ‘Unknown’ if unknown. 
 
18. If the patient did not receive both index test and reference standard, reasons for this 
Text; Specify ‘Unknown’ if unknown. 
 
